TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 63.3%

Neg 0% Neu 0% Pos 63.3%

TD Cowen analyst Marc Frahm maintains Puma Biotechnology (NASDAQ:PBYI) with a Hold and raises the price target from $5 to $6.